Price
$12.1
Decreased by -8.89%
Dollar Volume (20D)
63.18 M
ADR%
11.35
Earnings Report Date (estimate)
May 9, 24
Shares Float
50.42 M
Shares Outstanding
53.73 M
Shares Short
11.55 M
Market Cap.
652.81 M
Beta
-0
Price / Earnings
N/A
20D Range
8.02 14.84
50D Range
7.31 14.84
200D Range
2.09 14.84
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Nov 7, 23 -0.39
Increased by +18.75%
-0.42
Increased by +7.14%
Aug 10, 23 -0.32
Increased by +23.81%
-0.46
Increased by +30.43%
May 11, 23 -0.4
Increased by +9.09%
-0.48
Increased by +16.67%
Feb 28, 23 -0.43
Increased by +24.56%
-0.5
Increased by +14%
Nov 10, 22 -0.48
Increased by +40.74%
-0.5
Increased by +4%
Aug 11, 22 -0.42
Increased by +30%
-0.47
Increased by +10.64%
May 12, 22 -0.44
Decreased by -15.79%
-0.58
Increased by +24.14%
Mar 15, 22 -0.57
Decreased by -235.29%
-0.65
Increased by +12.31%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 23 362 K
Increased by +18 K%
-20.67 M
Increased by +12.1%
Decreased by -5.71 K%
Increased by +99.51%
Jun 30, 23 6 K
Decreased by -25%
-16.06 M
Increased by +18.96%
Decreased by -267.68 K%
Decreased by -8.05%
Mar 31, 23 21 K
Decreased by -34.38%
-18.39 M
Increased by +5.01%
Decreased by -87.58 K%
Decreased by -44.75%
Dec 31, 22 -110 K
Decreased by -103.36%
-20.23 M
Increased by +15.33%
Increased by +18.39 K%
Increased by +2.62 K%
Sep 30, 22 2 K
Decreased by -98.73%
-23.52 M
Increased by +29.83%
Decreased by -1.18 M%
Decreased by -5.43 K%
Jun 30, 22 8 K
Decreased by -94.19%
-19.82 M
Increased by +20.17%
Decreased by -247.74 K%
Decreased by -1.27 K%
Mar 31, 22 32 K
Decreased by -96.18%
-19.36 M
Decreased by -30.25%
Decreased by -60.5 K%
Decreased by -3.31 K%
Dec 31, 21 3.28 M
Increased by +41.72%
-23.89 M
Decreased by -124.91%
Decreased by -728.85%
Decreased by -58.7%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.